Arrowhead Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Arrowhead Pharmaceuticals Il CEO è Chris Anzalone, nominato in Dec2007, e ha un mandato di 16.92 anni. la retribuzione annua totale è $ 9.92M, composta da 9.1% di stipendio e 90.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.99% delle azioni della società, per un valore di $ 68.88M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.4 anni e 14 anni.

Informazioni chiave

Chris Anzalone

Amministratore delegato

US$9.9m

Compenso totale

Percentuale dello stipendio del CEO	9.1%
Mandato del CEO	16.9yrs
Proprietà del CEO	3.0%
Durata media del management	6.4yrs
Durata media del Consiglio di amministrazione	14yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Anzalone rispetto agli utili di Arrowhead Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$539m
Mar 31 2024	n/a	n/a	-US$471m
Dec 31 2023	n/a	n/a	-US$297m
Sep 30 2023	US$10m	US$903k	-US$205m
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 9.92M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 2.13M ).

Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Anzalone (55 yo)

16.9yrs

Mandato

US$9,918,093

Compensazione

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Anzalone	CEO, President & Director	16.9yrs	US$9.92m	2.99% $ 68.9m
Kenneth Myszkowski	Chief Financial Officer	14.8yrs	US$3.12m	0.19% $ 4.4m
Patrick O'Brien	COO, General Counsel & Secretary	9.9yrs	US$3.31m	0.23% $ 5.3m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$3.05m	0.16% $ 3.8m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	Nessun dato	Nessun dato
Vincent Anzalone	Head of Investor Relations & VP	no data	Nessun dato	Nessun dato
Howard Lovy	Director of Communications	19.3yrs	Nessun dato	Nessun dato
Bruce Given	Chief Medical Scientist	less than a year	US$16.34m	Nessun dato
Mark Seefeld	Head of Toxicology & VP	no data	Nessun dato	Nessun dato
Aaron Tan	Head of Tax	2.8yrs	Nessun dato	Nessun dato
Andy Davis	SVP of Cardiovascular & Head of Metabolic Franchise	no data	Nessun dato	Nessun dato
Nadia Meshkova	VP & Treasurer	2.8yrs	Nessun dato	Nessun dato

6.4yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di 0HI3 è esperto e expertise (durata media dell'incarico 6.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Anzalone	CEO, President & Director	16.9yrs	US$9.92m	2.99% $ 68.9m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	Nessun dato	Nessun dato
Douglass Given	Chairman of the Board	14yrs	US$474.60k	0.11% $ 2.6m
Michael Perry	Independent Lead Director	12.9yrs	US$459.60k	0.074% $ 1.7m
William Waddill	Independent Director	6.8yrs	US$469.60k	0.026% $ 609.6k
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Mauro Ferrari	Independent Director	14.3yrs	US$459.60k	0.037% $ 848.9k
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	Nessun dato	Nessun dato
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato

14.0yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0HI3 è composto da personale esperto e esperto (durata media dell'incarico 14 anni).

Arrowhead Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Chief Medical Officer recently sold US$567k worth of stock

Chief Financial Officer recently sold US$543k worth of stock

Chairman of the Board recently sold US$266k worth of stock

Recent updates

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 23% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 27% overvalued after recent price rise

First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023)

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

New major risk - Financial position

New major risk - Financial position

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022)

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Chief Medical Officer recently sold US$567k worth of stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Insider selling

Chief Financial Officer recently sold US$543k worth of stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022)

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Independent Director recently sold US$291k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chairman of the Board recently sold US$326k worth of stock

Chief Commercial Officer James Hassard has left the company

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020)

Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Chief Commercial Officer recently sold US$323k worth of stock

Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia